Diabetes

The digital health company specializes in diabetes management and is seeking to raise $100 million in its initial public offering.

Recent findings show the effectiveness of Abbott's FreeStyle Libre system in a real-world setting and provide insight into how the system can work toward improved health outcomes.

Although additional studies would have to be conducted, Fractyl Laboratories presented interim data at the American Diabetes Association's 79th Scientific Sessions that show its procedure could help eliminate the need for daily insulin injections...

The San Diego-based company is developing a continuous glucose monitoring patch. If approved, the device would compete against offerings from much larger players in the space like Dexcom, Abbott Laboratories, Medtronic, and Senseonics.

Data from the UK’s National Health Service EndoBarrier Service show a significant reduction in HbA1c, weight, liver fat, and cardiovascular disease risks as well as a reduction in the need for insulin in some patients.

The diabetes devices market is more competitive than ever before. Here's what we expect to see this year from the leading players in the space.

Tandem Diabetes Care has received a nod from FDA for the t:slim X2 insulin pump and the approval opens up a new device category – Alternate Controller Enabled Infusion Pumps.

Abbott CEO Miles White says the company is adding 300,000 new FreeStyle Libre patients per quarter and growing. More than 1.3 million diabetes patients are currently using the device for continuous glucose monitoring.

Under the collaboration, Livongo has the ability to offer the Freestyle Libre Pro System to those in its network, provided its appropriate and prescribed.